COVID-19 and diabetes cutaneous comorbidity

Area of Science:

• Infectious Diseases
• Endocrinology
• Dermatology

Background:

• Diabetes mellitus is a significant comorbidity associated with severe COVID-19 outcomes.
• Patients with diabetes exhibit heightened susceptibility to infections and poorer prognoses.
• Cutaneous manifestations in diabetic individuals during viral pandemics warrant specific investigation.

Purpose of the Study:

• To underscore the elevated risk of morbidity and mortality in diabetic patients with COVID-19.
• To emphasize the role of diabetes as a predictor of rapid disease progression and adverse prognosis.
• To highlight the necessity of researching the interplay between diabetes, its cutaneous complications, and SARS-CoV-2 infection.

Main Methods:

• Literature review focusing on studies examining COVID-19 in diabetic populations.
• Analysis of data correlating diabetes status with COVID-19 severity and outcomes.
• Review of reported cutaneous complications in diabetic patients infected with SARS-CoV-2.

Main Results:

• Diabetic patients demonstrate a statistically significant higher risk of severe COVID-19, hospitalization, and mortality.
• Diabetes is identified as a critical risk factor for rapid COVID-19 progression and unfavorable prognosis.
• A growing body of evidence suggests unique cutaneous manifestations associated with COVID-19 in individuals with diabetes.

Conclusions:

• Diabetes is a crucial factor influencing COVID-19 severity and patient outcomes.
• Special attention must be directed towards managing diabetes in the context of SARS-CoV-2 infection.
• Further research into the specific cutaneous complications of COVID-19 in diabetic patients is essential for comprehensive patient care.